The most common grade 3 to 4 adverse events other than neutropenia included leukopenia (24.8% vs.
0%), anemia (5.4% vs.
1.8%), and fatigue (1.8% vs.
0.5%).
Ribociclib, another CDK4/6 inhibitor, has also been tested in the first-line setting for postmenopausal patients and premenopausal patients with HER2-negative hormone receptorâ€“positive, recurrent or metastatic breast cancer.
Evidence (first-line ribociclib and endocrine therapy): The phase III placebo-controlledMONALEESA-2trial (NCT01958021) randomly assigned 668 patients to receive either first-line ribociclib plus letrozole or placebo plus letrozole.[12,13]The primary end point (investigator-assessed PFS) was met.